These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33236691)

  • 21. Evaluation of safety and early efficacy of AAV gene therapy in mouse models of vanishing white matter disease.
    Herstine JA; Chang PK; Chornyy S; Stevenson TJ; Sunshine AC; Nokhrina K; Rediger J; Wentz J; Vetter TA; Scholl E; Holaway C; Pyne NK; Bratasz A; Yeoh S; Flanigan KM; Bonkowsky JL; Bradbury AM
    Mol Ther; 2024 Jun; 32(6):1701-1720. PubMed ID: 38549375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. eIF2B: recent structural and functional insights into a key regulator of translation.
    Wortham NC; Proud CG
    Biochem Soc Trans; 2015 Dec; 43(6):1234-40. PubMed ID: 26614666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human-induced pluripotent stem cell-derived cerebral organoid of leukoencephalopathy with vanishing white matter.
    Deng J; Zhang J; Gao K; Zhou L; Jiang Y; Wang J; Wu Y
    CNS Neurosci Ther; 2023 Apr; 29(4):1049-1066. PubMed ID: 36650674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Proteome Research in a Zebrafish Model for Vanishing White Matter Disease.
    Kim D; Lee YR; Choi TI; Kim SH; Kang HC; Kim CH; Lee S
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Eukaryotic translation initiation factor 2B and leukoencephalopathy with vanishing white matter].
    Pan YX; Wu Y; Niu ZP; Jiang YW
    Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):608-10. PubMed ID: 19829687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of DNL343: A Potent, Selective, and Brain-Penetrant eIF2B Activator Designed for the Treatment of Neurodegenerative Diseases.
    Craig RA; De Vicente J; Estrada AA; Feng JA; Lexa KW; Canet MJ; Dowdle WE; Erickson RI; Flores BN; Haddick PCG; Kane LA; Lewcock JW; Moerke NJ; Poda SB; Sweeney Z; Takahashi RH; Tong V; Wang J; Yulyaningsih E; Solanoy H; Scearce-Levie K; Sanchez PE; Tang L; Xu M; Zhang R; Osipov M
    J Med Chem; 2024 Apr; 67(7):5758-5782. PubMed ID: 38511649
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Affected astrocytes in the spinal cord of the leukodystrophy vanishing white matter.
    Leferink PS; Breeuwsma N; Bugiani M; van der Knaap MS; Heine VM
    Glia; 2018 Apr; 66(4):862-873. PubMed ID: 29285798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired eukaryotic translation initiation factor 2B activity specifically in oligodendrocytes reproduces the pathology of vanishing white matter disease in mice.
    Lin Y; Pang X; Huang G; Jamison S; Fang J; Harding HP; Ron D; Lin W
    J Neurosci; 2014 Sep; 34(36):12182-91. PubMed ID: 25186761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Japanese girl with an early-infantile onset vanishing white matter disease resembling Cree leukoencephalopathy.
    Takano K; Tsuyusaki Y; Sato M; Takagi M; Anzai R; Okuda M; Iai M; Yamashita S; Okabe T; Aida N; Tsurusaki Y; Saitsu H; Matsumoto N; Osaka H
    Brain Dev; 2015 Jun; 37(6):638-42. PubMed ID: 25457085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genotypic and phenotypic characteristics of juvenile/adult onset vanishing white matter: a series of 14 Chinese patients.
    Ren Y; Yu X; Chen B; Tang H; Niu S; Wang X; Pan H; Zhang Z
    Neurol Sci; 2022 Aug; 43(8):4961-4977. PubMed ID: 35389136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The small molecule ISRIB rescues the stability and activity of Vanishing White Matter Disease eIF2B mutant complexes.
    Wong YL; LeBon L; Edalji R; Lim HB; Sun C; Sidrauski C
    Elife; 2018 Feb; 7():. PubMed ID: 29489452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy Trial Design in Vanishing White Matter: An Expert Consortium Opinion.
    van der Knaap MS; Bonkowsky JL; Vanderver A; Schiffmann R; Krägeloh-Mann I; Bertini E; Bernard G; Fatemi SA; Wolf NI; Saunier-Vivar E; Rauner R; Dekker H; van Bokhoven P; van de Ven P; Leferink PS
    Neurol Genet; 2022 Apr; 8(2):e657. PubMed ID: 35128050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNL343 is an investigational CNS penetrant eukaryotic initiation factor 2B activator that prevents and reverses the effects of neurodegeneration caused by the integrated stress response.
    Yulyaningsih E; Suh JH; Fanok M; Chau R; Solanoy H; Takahashi R; Bakardjiev AI; Becerra I; Benitez NB; Chiu CL; Davis SS; Dowdle WE; Earr T; Estrada AA; Gill A; Ha C; Haddick PCG; Henne KR; Larhammar M; Leung AW; Maciuca R; Memarzadeh B; Nguyen HN; Nugent AA; Osipov M; Ran Y; Rebadulla K; Roche E; Sandmann T; Wang J; Lewcock JW; Scearce-Levie K; Kane LA; Sanchez PE
    Elife; 2024 Sep; 12():. PubMed ID: 39287504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vanishing white matter: a leukodystrophy due to astrocytic dysfunction.
    Bugiani M; Vuong C; Breur M; van der Knaap MS
    Brain Pathol; 2018 May; 28(3):408-421. PubMed ID: 29740943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant eIF2B leads to impaired mitochondrial oxidative phosphorylation in vanishing white matter disease.
    Raini G; Sharet R; Herrero M; Atzmon A; Shenoy A; Geiger T; Elroy-Stein O
    J Neurochem; 2017 Jun; 141(5):694-707. PubMed ID: 28306143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations linked to leukoencephalopathy with vanishing white matter impair the function of the eukaryotic initiation factor 2B complex in diverse ways.
    Li W; Wang X; Van Der Knaap MS; Proud CG
    Mol Cell Biol; 2004 Apr; 24(8):3295-306. PubMed ID: 15060152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic and Metabolomic Analyses of Vanishing White Matter Mouse Astrocytes Reveal Deregulation of ER Functions.
    Wisse LE; Penning R; Zaal EA; van Berkel CGM; Ter Braak TJ; Polder E; Kenney JW; Proud CG; Berkers CR; Altelaar MAF; Speijer D; van der Knaap MS; Abbink TEM
    Front Cell Neurosci; 2017; 11():411. PubMed ID: 29375313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A yeast purification system for human translation initiation factors eIF2 and eIF2Bε and their use in the diagnosis of CACH/VWM disease.
    de Almeida RA; Fogli A; Gaillard M; Scheper GC; Boesflug-Tanguy O; Pavitt GD
    PLoS One; 2013; 8(1):e53958. PubMed ID: 23335982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vanishing white matter: Eukaryotic initiation factor 2B model and the impact of missense mutations.
    Slynko I; Nguyen S; Hamilton EMC; Wisse LE; de Esch IJP; de Graaf C; Bruning JB; Proud CG; Abbink TEM; van der Knaap MS
    Mol Genet Genomic Med; 2021 Mar; 9(3):e1593. PubMed ID: 33432707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutational analysis of the alpha subunit of eIF2B provides insights into the role of eIF2B bodies in translational control and VWM disease.
    Norris K; Hodgson RE; Dornelles T; Allen KE; Abell BM; Ashe MP; Campbell SG
    J Biol Chem; 2021; 296():100207. PubMed ID: 33334879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.